Live Biotherapeutics Drug Discovery Services for Diabetes Mellitus
It has been revealed that gut microbiome dysbiosis has made a great contribution to the pathogenesis of diabetes mellitus, especially type 2 diabetes. As a world-leading services provider, Creative Biolabs is dedicated to helping customers in probiotic-based therapy development for diabetes treatment by offering high-quality products and services.
Diabetes Mellitus Overview
Diabetes mellitus (DM), also known as diabetes, is a long-term metabolic disease with a property of an elevated blood glucose level, which causes a series of serious complications over time. As a prevalent disease, DM mainly affects the elderly and adults with a dramatically increased morbidity rate in the past few decades, especially in low- and middle-income countries. In the USA, about 34.2 million people are living with DM, meaning 1 in 10 people have diabetes.
Symptoms of DM are characterized by increased urination, increased thirst, increased appetite, and decreased weight. If controlled inadequately, DM will cause a wide range of complications, including renal and cardiovascular diseases, neurological disorders, eye damage, and so forth. Type 1 diabetes (T1DM) and type 2 diabetes (T2DM) are two common types of DM, according to whether insulin secretion or not by the pancreas.
Diabetes Mellitus Treatment Using Probiotics
As one of the leading causes of death in the world, the exact pathogenesis of DM is uncertain up to now. T1DM is mainly caused by insulin deficiency due to the immune-mediated destruction of β-islet cells or genetic factors. Meanwhile, T2DM is usually caused by insulin resistance or lack of insulin due to various factors, among which microbial imbalance or dysbiosis has been demonstrated to be closely associated with glucose metabolism and T2DM pathogenesis through several molecular mechanisms (see Fig.2). By modulating intestinal permeability and inflammation, affecting the metabolism of glucose and lipid, and influencing insulin sensitivity, the gut microbes play both pathologic and therapeutic effects on T2DM.
Fig.2 Overview of how a dysbiotic gut microbiota can promote type 2 diabetes (a) and how microbiota-based therapies might treat and/or prevent this disorder (b). (Adeshirlarijaney, 2020)
Probiotics, a group of beneficial live microorganisms, exert multiple positive health effects for the control and treatment of DM, particularly T2DM. Currently, the most widely investigated probiotics for DM amelioration by experimental studies and clinical trials are Bifidobacterium spp. and Lactobacillus spp.
-
Firstly, restoring healthy intestinal microbiota profile or abundance can effectively ameliorate T2DM, by which probiotics inhibit the growth of pathological bacteria and related microbial products.
-
Secondly, some probiotic species, such as Bacteroides vulgatus and Akkermansia muciniphila, inhibit glucose intake by reducing gut permeability and improving intestinal barrier functions.
-
Then, probiotics supplementation improves the metabolism and synthesis of glucose. For example, Bifidobacterium lactis effectively increase glycogen synthesis while decreasing the expression of hepatic gluconeogenesis-related genes.
-
Other possible antidiabetic mechanisms include inhibition pro-inflammatory cytokines, increase fatty acid oxidation, decrease insulin resistance, modification of pH balance in the gastrointestinal tract, etc.
Probiotics-Based Therapy Services
Creative Biolabs is a leading global biologics company established in the United States. With more than a decade of exploration and expansion, we offer comprehensive one-stop solutions for drug discovery. Armed with a state-of-the-art technology platform and Ph.D. scientists, Creative Biolabs provides custom, standardized, and reliable services for probiotics-based therapy for diabetes mellitus treatment. Besides, our tailored service covers all aspects from abundant probiotic species and related analytical and qualification services.
Our project procedure is designed to meet your special requirements. You can contact us to speak to our expert technical team about your needs.
References
-
Adeshirlarijaney, A., Gewirtz, A.T. Considering gut microbiota in treatment of type 2 diabetes mellitus. Gut Microbes. 2020, 11(3): 253-264.
-
Gurung, M., et al. Role of gut microbiota in type 2 diabetes pathophysiology. EBioMedicine. 2020, 51: 10259.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Related Services
